 LEXINGTON, Mass., Oct. 6, 2021 PRNewswire -- Curis, Inc. NASDAQ: CRIS, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 106,350 shares of Curis common stock to five new employees, with a grant date of October 1, 2021 the Q4 2021 Inducement Grants. 